Combined Effects of Behavioral Intervention and Tolterodine in Patients Dissatisfied With Overactive Bladder Medication

Journal of Urology

Volumn 181, Issue 6, 2009, Pages 2599-2607

  Klutke, Carl G ^a   Burgio, Kathryn L ^b   Wyman, Jean F ^c   Guan, Zhonghong ^d   Sun, Franklin ^d   Berriman, Sandra ^d   Bavendam, Tamara ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d PFIZER INC   (United States)

Author keywords

combination therapy; health behavior; overactive; tolterodine; urge; urinary bladder; urinary incontinence

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONSTIPATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OVERACTIVE BLADDER; PATIENT EDUCATION; PATIENT SATISFACTION; POLLAKISURIA; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; SYMPTOM; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BEHAVIOR THERAPY; BENZHYDRYL COMPOUNDS; COMBINED MODALITY THERAPY; CRESOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 67349273769     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.02.028     Document Type: Article

References (20)

1. Abrams P., Artibani W., Cardozo L., Dmochowski R., van Kerrebroeck P., and Sand P. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 25 (2006) 293
2. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306
3. Coyne K.S., Sexton C.C., Irwin D.E., Kopp Z.S., Kelleher C.J., and Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101 (2008) 1388
4. Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., and Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54 (2008) 543
5. Noe L., Sneeringer R., Patel B., and Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 17 (2004) 54
6. Milne J.L. Behavioral therapies for overactive bladder: making sense of the evidence. J Wound Ostomy Continence Nurs 35 (2008) 93
7. Burgio K.L. Behavioral treatment options for urinary incontinence. Gastroenterology 126 (2004) S82
8. Wyman J.F., Fantl J.A., McClish D.K., and Bump R.C. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 179 (1998) 999
9. Burgio K.L., Locher J.L., Goode P.S., Hardin J.M., McDowell B.J., Dombrowski M., et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 280 (1998) 1995
10. Burgio K.L., Goode P.S., Locher J.L., Umlauf M.G., Roth D.L., Richter H.E., et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 288 (2002) 2293
11. Mattiasson A., Blaakaer J., Hoye K., and Wein A.J. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 91 (2003) 54
12. Herschorn S., Becker D., Miller E., Thompson M., and Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol 11 (2004) 2430
13. Burgio K.L., Locher J.L., and Goode P.S. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 48 (2000) 370
14. Coyne K.S., Matza L.S., Kopp Z., and Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49 (2006) 1079
15. Coyne K.S., Tubaro A., Brubaker L., and Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 68 (2006) 9
16. Pleil A.M., Coyne K.S., Reese P.R., Jumadilova Z., Rovner E.S., and Kelleher C.J. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue-the BSW. Value Health 8 (2005) S25
17. Elinoff V., Bavendam T., Glasser D.B., Carlsson M., Eyland N., and Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 60 (2006) 745
18. Chancellor M.B., Kianifard F., Beamer E., Mongay L., Ebinger U., Hicks G., et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a behavioural modification programme upon the symptoms of overactive bladder. Int J Clin Pract 62 (2008) 606
19. Burgio K.L., Kraus S.R., Menefee S., Borello-France D., Corton M., Johnson H.W., et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 149 (2008) 161
20. Klutke C., Wyman J., Harding G., Burgio K., Vats V., and Coyne K.S. Factors that contribute to treatment satisfaction in patients with overactive bladder (2008) Presented at annual meeting of International Urogynecology Association, Taipei, Taiwan, September 15-17